By Nathan Allen

Sanofi SA (SAN.FR) said Monday that it has concluded the research-and-option phase of its rare-disease alliance with Alnylam Pharmaceuticals Inc. (ALNY)

Through the alliance, which was set up in 2014, the companies developed a treatment for patients with ATTR amyloidosis and are testing a molecule to treat hemophilia, Sanofi said.

In the new phase of the alliance Alnylam will proceed with another early-stage therapy for an undisclosed rare disease, taking it through to initial trials.

Sanofi said it will then be responsible for any further development of the therapy, paying royalties to Alnylam from global sales.

The two companies have amended their equity agreement, with France's Sanofi obtaining a release from its lock-up of trading in Alnylam's shares.

Write to Nathan Allen at nathan.allen@dowjones.com

(END) Dow Jones Newswires

April 08, 2019 01:31 ET (05:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Sanofi
Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Sanofi